The JDP2 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line, providing targeted disruption of the JDP2 gene. This loss-of-function model is suitable for investigating JDP2-dependent transcriptional regulation and its downstream biological effects in cancer research.
The host A-549 cell line, derived from a lung adenocarcinoma patient, is an adherent epithelial line widely used in respiratory and cancer research. It serves as a standard model for drug response, tumorigenesis, and signal transduction studies, and is responsive to stimuli such as TNF-alpha and oxidative stress, making it a relevant platform for examining JDP2 function.
JDP2 encodes a basic leucine zipper transcription factor that represses AP-1-dependent transcription by forming inactive heterodimers with c-Jun, JunB, JunD, and ATF2, competing for DNA binding and downregulating target genes. Its activity is modulated by upstream kinases JNK and p38 MAPK, which are activated by TNF-alpha, UV radiation, and oxidative stress. Key downstream targets include CCNA2, CCNB1, CDKN1A (p21), BCL2L1, MMP1, and IL-8. JDP2 also interacts with co-regulators p300 and HDAC, linking it to chromatin remodeling. In this network, JDP2 acts downstream of JNK and c-Jun and upstream of p53 and p21, integrating stress signals to control proliferation and survival.
In A-549 cells, JDP2 disruption relieves AP-1 repression, enhancing expression of AP-1 target genes. This can alter cell cycle progression, apoptosis sensitivity, and epithelial-mesenchymal transition (EMT) markers. Given AP-1’s role in lung cancer progression and therapy, this model aids in dissecting JDP2-mediated tumor cell behavior. The polyclonal nature may reveal phenotypic variability associated with editing outcomes.
Researchers can employ this model to study transcriptional regulation, signal transduction, and cancer biology. Western blotting detects changes in AP-1 proteins like c-Jun and JunB; RT-qPCR quantifies downstream targets such as CCNA2 and CDKN1A. AP-1 activity can be measured by dual-luciferase reporter assays. Flow cytometry enables cell cycle analysis, and apoptosis is assessed by Annexin V/PI staining. Migration/invasion assays explore EMT, and RNA-seq provides transcriptomic profiling. These applications support drug resistance, inflammatory signaling, and tumor progression research. For further details, contact Ascent Research.
